为解决胰腺癌免疫治疗难题，约翰霍普金斯大学医学院等机构的研究人员开展了胰腺癌肝肺转移小鼠模型对 IL-1β 阻断反应的研究。结果显示联合疗法效果因转移部位而异，该研究为胰腺癌免疫治疗提供新思路，值得科研人员一读。

Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer.

本文研究强调了MICAL2影响PDAC生物学特性的多种途径 ... 上题为“MICAL2 Promotes Pancreatic Cancer Growth and Metastasis”的研究报告中，来自加利福尼亚大学 ...

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed ...

Interestingly, about 10% of PDAC patients who develop lung metastasis survive longer than those with metastasis to other organs, particularly the liver. In some cases, PDAC patients with untreated ...

Major advances in cancer control will be greatly aided by early detection for diagnosing and treating cancer in its preinvasive state before metastasis. Unfortunately, for pancreatic ductal ...

treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine+nab-paclitaxel (GnP). Changes in peri-operative chemotherapy and radiation use ...

About GOBLET Cohort 5 The mFOLFIRINOX cohort of the Phase 1/2 GOBLET study is designed to evaluate newly diagnosed metastatic PDAC patients treated with pelareorep + mFOLFIRINOX with or without ...